中国仓鼠卵巢细胞
生物制药
单克隆抗体
糖蛋白
糖基化
聚糖
重组DNA
计算生物学
细胞生物学
生物
抗体
细胞培养
生物技术
免疫学
生物化学
分子生物学
基因
遗传学
作者
Marie-Eve Lalonde,Yves Durocher
标识
DOI:10.1016/j.jbiotec.2017.04.028
摘要
Over the last years, the biopharmaceutical industry has significantly turned its biologics production towards mammalian cell expression systems. The presence of glycosylation machineries within these systems, and the fact that monoclonal antibodies represent today the vast majority of new therapeutic candidates, has largely influenced this new direction. Recombinant glycoproteins, including monoclonal antibodies, have shown different biological properties based on their glycan profiles. Thus, the industry has developed cell engineering strategies not only to improve cell's specific productivity, but also to adapt their glycosylation profiles for increased therapeutic activity. Additionally, the advance of "omics" technologies has recently given rise to new possibilities in improving these expression platforms and will significantly help developing new strategies, in particular for CHO (Chinese Hamster Ovary) cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI